ReviewStem cell reviews and reports2011
Immunological barriers to stem-cell based cardiac repair.
Review in Stem cell reviews and reports, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 27 citations in OpenAlex.
- Macrophage tracking with USPIO imaging and T2 mapping predicts immune rejection of transplanted stem cells.Scientific reports · 2024Article
- Nanotechnology in interventional cardiology: A state-of-the-art review.International journal of cardiology. Heart & vasculature · 2022Review
- Immunomodulation for optimal cardiac regeneration: insights from comparative analyses.NPJ Regenerative medicine · 2021Review
- Magnetic resonance imaging of stem cell-macrophage interactions with ferumoxytol and ferumoxytol-derived nanoparticles.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2019Review
- Detection of Stem Cell Transplant Rejection with Ferumoxytol MR Imaging: Correlation of MR Imaging Findings with Those at Intravital Microscopy.Radiology · 2017Article
- Teratocarcinomas Arising from Allogeneic Induced Pluripotent Stem Cell-Derived Cardiac Tissue Constructs Provoked Host Immune Rejection in Mice.Scientific reports · 2016Article
- HLA Class I Depleted hESC as a Source of Hypoimmunogenic Cells for Tissue Engineering Applications.Tissue engineering. Part A · 2015Article
- Downregulation of beta-microglobulin to diminish T-lymphocyte lysis of non-syngeneic cell sources of engineered heart tissue constructs.Biomedical materials (Bristol, England) · 2015Article
- Thinking Outside the Heart: Use of Engineered Cardiac Tissue for the Treatment of Chronic Deep Venous Insufficiency.Journal of cardiovascular pharmacology and therapeutics · 2014Article
- Perspectives on stem cell-based elastic matrix regenerative therapies for abdominal aortic aneurysms.Stem cells translational medicine · 2013Article
- Concise review: immunologic lessons from solid organ transplantation for stem cell-based therapies.Stem cells translational medicine · 2013Review
- Intravenous ferumoxytol allows noninvasive MR imaging monitoring of macrophage migration into stem cell transplants.Radiology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Repair of damaged myocardium with pluripotent stem cell derived cardiomyocytes is becoming increasingly more feasible. Developments in stem cell research emphasize the need to address the foreseeable problem of immune rejection following transplantation. Pluripotent stem cell (PSC) derived cardiomyocytes have unique immune characteristics, some of which are not advantageous for transplantation. Here we review the possible mechanisms of PSC-derived cardiomyocytes rejection, summarize the current knowledge pertaining to immunogenicity of such cells and describe the existing controversies. Myocardial graft rejection can be reduced by modifying PSCs prior to their differentiation into cardiomyocytes. Overall, this approach facilitates the development of universal donor stem cells suitable for the regeneration of many different tissue types.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.